Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2280)	2/22/2008 3:11:53 PM
From: Jibacoa	Respond to of 3722

ENDP Opened with a little UG & is up 7.2% on volume of 2,768,210 > 2x its ADV. bigcharts.marketwatch.com It reported its 4thQ results , which showed that earnings increased 24% from 2006 on a 17% improvement on revenues. Net income was $50.6M ($0.38) vs. $14.8M ($0.11) in 2006 Of course, the 2006 Q had charges of $57M related to the drugs Depodur and Synera, and the acquisition of RxKinetix <g> It raised its 2008 guidance & now sees sales of $1.225B to $1.250B, up from its previous estimates of $1.215B to $1.24B The PE is around 13 & the EE around $2.10 & $2.45 in 2008 & 2009 vs. the $1.92 in 2007 The stock seems to have support at the $25 level.The "analysts" target is around $35, although the stock has resistance at the $39 level.<g> On a close above $35 the stock will make an all time H. bigcharts.marketwatch.com Bernard